Risk of coronary artery stenosis in Iranian type 2 diabetics: is there a role for matrix metalloproteinase-3 gene (-1612 5A/6A) polymorphism?

Beyzade S, Zhang S, Wong YK, Day IN, Eriksson P, Ye S (2003) Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol 41:2130–2137

Bini A, Mann KG, Kudryk BJ, Schoen FJ (1999) Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 19:1852–1861

Borghaei RC, Sullivan C, Mochan E (1999) Identification of a cytokineinduced repressor of interleukin-1 stimulated expression of stromelysin 1 (MMP-3). J Biol Chem 274:2126–2131

de Maat MP, Jukema JW, Ye S et al (1999) Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 83:852–856

Friedewald WT, Levi IR, Fredrickson DS (1972) Estimation of low density lipoprotein cholesterol levels in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499–502

Galis ZS, Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90:251–262

Galis ZS, Sukhova GK, Lark MW, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94:2493–2503

Gensini GF, Comeglio M, Colella A (1998) Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur Heart J 19:53–61

Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ (1987) Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316:1371–1375

Henney AM, Wakeley PR, Davies MJ et al (1991) Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci 88:8154–8158

Hirashiki A, Yamada Y, Murase Y, Suzuki Y, Kataoka H, Morimoto Y, Tajika T, Murohara T, Yokota M (2003) Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J Am Coll Cardiol 42:1429–1437

Humphries SE, Luong LA, Talmud PJ et al (1998) The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial. Atherosclerosis 139:49–56

Irace C, Cortese C, Migale M et al (2008) Stromelysin gene promoter polymorphism and common carotid geometry in diabetic subjects. Int Angiol 27(5):413–418

Kim JS, Park HY, Kwon JH, Im EK, Choi D, Jang Y, Cho SY (2002) The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina. Yonsei Med J 43:473–481

Kirstein M, Sanz L, Quinones S, Moscat J, Diaz-Meco MT, Saus J (1996) Cross-talk between different enhancer elements during mitogenic induction of the human stromelysin-1 gene. J Biol Chem 271:18231–18236

Liu PY, Chen JH, Li YH, Wu HL, Shi GY (2003) Synergistic effect of stromelysin-1 (matrix metallo-proteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction. Thromb Haemost 90:132–139

Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U (1994) Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 330:1041–1046

Matrisian LM (1990) Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6:121–125

Medley TL, Kingwell BA, Gatzka CD, Pillay P, Cole TJ (2003) Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 92:1254–1261

Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215–1219

Murphy G, Reynolds JJ, Royce PM, Steinman B (1993) Extracellular matrix degradation. In: Connective tissue and its heritable disorders. Wiley-Liss, New York, pp 287–316

Murphy G, Ward R, Gavrilovic J, Atkinson S (1992) Physiological mechanism for metalloproteinase activation. Matrix suppl 1:224–230

Nojiri T, Morita H, Imai Y et al (2003) Genetic variations of matrix metalloproteinase-1 and-3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int J Cardiol 92:181–186

Oceandy D, Yusoff R, Baudoin FM, Neyses L, Ray SG (2007) Promoter polymorphism of the matrix metalloproteinase 3 gene is associated with regurgitation and left ventricular remodeling in mitral valve prolapse patients. European Journal of Heart Failure 9:1010–1017

Polak JF, Kronmal RA, Tell GS, O’Leary DH, Savage PJ, Gardin JM, Rutan GH, Borhani NO, on behalf of the Cardiovascular Health Study (1996) Compensatory increase in common carotid artery diameter: relation to blood pressure and artery intima-media thickness in older adults. Stroke 27:2012–2015

Pollanen PJ, Lehtimaki T, Ilveskoski E et al (2002) Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase: 3. The Helsinki Sudden Death Study. Atherosclerosis 164:329–335

Quinones S, Buttice G, Kurkinen M (1994) Promoter elements in the transcriptional activation of the human stromelysin-1 gene by the inflammatory cytokine, interleukin 1. Biochem J 302(Pt 2):471–477

Quinones S, Saus J, Otani Y, Harris ED Jr, Kurkinen M (1989) Transcriptional regulation of human stromelysin. J Biol Chem 264:8339–8344

Schwarz A, Haberbosch W, Tillmanns H, Gardemann A (2002) The stromelysin-1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease. Dis Markers 18:121–128

Sirum-Connolly K, Brinckerhoff CE (1991) Interleukin-1 or phorbol induction of the stromelysin promoter requires an element that cooperates with AP-1. Nucleic Acids Res 19:335–341

Steinke W, Els T, Hennerici M (1994) Compensatory carotid artery dilation in atherosclerosis. Circulation 89:2578–2581

Terashima M, Akita H, Kanazawa K et al (1999) Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 99:2717–2719

Woessner JF Jr (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145–2154

Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM (1996) Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter, which results in reduced gene expression. J Biol Chem 271:13055–13060

Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM (1995) Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 73:209–215

ZhuC OJ, HamstenA EP (2006) Allele-specific MMP-3 transcription under in vivo conditions. Biochem Biophys Res Commun 348:1150–1156